These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 12832230

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Chronic Demyelination and Axonal Degeneration in Multiple Sclerosis: Pathogenesis and Therapeutic Implications.
    Simkins TJ, Duncan GJ, Bourdette D.
    Curr Neurol Neurosci Rep; 2021 Apr 09; 21(6):26. PubMed ID: 33835275
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis.
    Peterson LK, Fujinami RS.
    J Neuroimmunol; 2007 Mar 09; 184(1-2):37-44. PubMed ID: 17196667
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Tyr-MIF-1 attenuates development of tolerance to spiperone-induced catalepsy in rats.
    Kostrzewa RM, Kastin AJ.
    Brain Res Bull; 1993 Mar 09; 31(6):707-12. PubMed ID: 8100182
    [Abstract] [Full Text] [Related]

  • 31. Behavioral effects of dopamine agonists and antagonists in MPTP-lesioned D3 receptor knockout mice.
    Yarkov AV, Hanger D, Reploge M, Joyce JN.
    Pharmacol Biochem Behav; 2003 Dec 09; 76(3-4):551-62. PubMed ID: 14643855
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Greater loss of axons in primary progressive multiple sclerosis plaques compared to secondary progressive disease.
    Tallantyre EC, Bø L, Al-Rawashdeh O, Owens T, Polman CH, Lowe J, Evangelou N.
    Brain; 2009 May 09; 132(Pt 5):1190-9. PubMed ID: 19420101
    [Abstract] [Full Text] [Related]

  • 35. Conditioning to injection procedures and repeated testing increase SCH 23390-induced catalepsy in mice.
    Chinen CC, Frussa-Filho R.
    Neuropsychopharmacology; 1999 Nov 09; 21(5):670-8. PubMed ID: 10516963
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Effects of sigma(1) receptor ligand MS-377 on D(2) antagonists-induced behaviors.
    Karasawa J, Takahashi S, Takagi K, Horikomi K.
    Pharmacol Biochem Behav; 2002 Oct 09; 73(3):505-10. PubMed ID: 12151023
    [Abstract] [Full Text] [Related]

  • 38. Mechanisms of primary axonal damage in a viral model of multiple sclerosis.
    Das Sarma J, Kenyon LC, Hingley ST, Shindler KS.
    J Neurosci; 2009 Aug 19; 29(33):10272-80. PubMed ID: 19692601
    [Abstract] [Full Text] [Related]

  • 39. Inhibitory effects of MK-801 on contextual sensitization to climbing behavior and on development of tolerance to hypothermia induced by a single high dose of apomorphine.
    Yun JS, Kim HS, Lee MK, Oh KW, Jang CG, Park WK, Seong YH, Lee SC, Oh SK.
    Pharmacol Res; 2001 Dec 19; 44(6):473-9. PubMed ID: 11735353
    [Abstract] [Full Text] [Related]

  • 40. Selective D2 dopamine receptor agonists prevent catalepsy induced by SCH 23390, a selective D1 antagonist.
    Meller E, Kuga S, Friedhoff AJ, Goldstein M.
    Life Sci; 1985 May 13; 36(19):1857-64. PubMed ID: 3157851
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.